Basiliximab (Simulect)

A chimeric mouse-human monoclonal antibody to the α chain (CD25) of the IL-2 receptor of T cells.

Used to prevent rejection in organ transplantation, especially in kidney transplants.

It is a chimeric CD 25 monoclonal antibody of the IgG1 isotype.

Acts as an antagonist at the interleukin-2(IL-2) binding site of the p55 subunit (Tac antigen) of the high affinity IL-2 receptor (CD 25) on the surface of the activated T lymphocytes.

The drug is first given within 2 hours of the start of the transplant operation and the second 4 days after the transplant attempting to saturate the receptors and prevent T cells from replication and also from activating B cells responsible for the production of antibodies, which bind to the transplanted organ and stimulate an immune response against the transplant.

Reduces the incidence and severity of acute rejection in kidney transplantation without increasing the incidence of opportunistic infections.

Leave a Reply

Your email address will not be published. Required fields are marked *